A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 13, 2019

Primary Completion Date

January 10, 2020

Study Completion Date

January 10, 2020

Conditions

Healthy Volunteer

Interventions

DRUG

BIIB091

Administered as specified in the treatment arm.

DRUG

Placebo

Administered as specified in the treatment arm.

Trial Locations (1)

Research Site, Dallas